PALO ALTO, Calif., March 20, 2024 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.

加利福尼亚州帕洛阿尔托，2024年3月20日/PRNewswire/--Evommune，Inc.是一家发现和开发治疗免疫介导的炎症性疾病新方法的生物技术公司，今天宣布，它已与Maruho Co.，Ltd.展开扩大的战略合作，专门在大中华区和其他主要亚洲国家开发和商业化EVO756。

The two companies previously entered into a similar agreement for Japan in September, 2023. Under the terms of the new agreement, Evommune is eligible to receive up to $62 million, including a significant upfront and customary milestone payments.

这两家公司此前于2023年9月为日本签订了类似协议。根据新协议的条款，Evommune有资格获得高达6200万美元的预付款和常规里程碑付款。

EVO756, Evommune's MRGPRX2 antagonist, is an investigational therapy targeting MRGPRX2 for multiple inflammatory conditions, with the potential to be a first-in-class oral treatment for a variety of mast cell mediated disease, including chronic spontaneous urticaria.

Evommune的MRGPRX2拮抗剂EVO756是一种针对MRGPRX2治疗多种炎症的研究性疗法，有可能成为多种肥大细胞介导的疾病（包括慢性自发性荨麻疹）的一流口服疗法。

Evommune has initiated its Phase 1 first-in-human trial, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU). The trial is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open label study in adults with CSU.

Evommune已启动其第一阶段人体试验，评估健康成人和慢性自发性荨麻疹（CSU）成人的EVO756。该试验是一项针对正常健康成年人的随机，双盲，安慰剂对照单次和多次递增剂量（SAD和MAD）研究，以及针对CSU成年人的开放标签研究。

The trial is designed to assess the safety, tolerability and pharmacokinetics, of orally administered EVO756, as well as the pharmacodynamic potential of EVO756 on mast cell degranulation via a skin challenge test, with data expected in the first half of 2024.

该试验旨在评估口服EVO756的安全性、耐受性和药代动力学，以及EVO756通过皮肤激发试验对肥大细胞脱颗粒的药效学潜力，预计数据将在2024年上半年公布。

'The collaboration with Maruho gives full recognition to the strenghths of both companies, accelerating the delivery of R&D innovation, and jointly bringing transformative medicines to benefit chronic inflammatory disease patients in Asia and globally,' said Greg Moss, Chief Corporate Strategy & Legal Officer at Evommune.

Evommune首席企业战略和法律官格雷格·莫斯（Greg Moss）说：“与Maruho的合作充分肯定了两家公司的实力，加快了研发创新的交付，并共同带来了变革性药物，使亚洲和全球的慢性炎症患者受益。”

'Maruho's recognition of the potential of EVO756 has allowed us to attract substantial non-dilutive capital, which will be used to support our strategy to expand our pipeline with novel therapies designed to treat and halt the progression of chronic inflamatory diseases.

“Maruho对EVO756潜力的认识使我们能够吸引大量非稀释性资本，这些资本将用于支持我们的战略，以扩大我们的渠道，采用旨在治疗和阻止慢性炎症疾病进展的新型疗法。”

About EVO756

关于EVO756

EVO756 is a potent, highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2). MRGPRX2 is most abundantly found on mast cells and peripheral sensory neurons. MRGPRX2 can trigger IgE-independent activation (degranulation), which can lead to a variety of symptoms depending on the tissue that is affected.

EVO756是mas相关G蛋白偶联受体X2（MRGPRX2）的有效，高选择性小分子拮抗剂。MRGPRX2在肥大细胞和外周感觉神经元上最为丰富。MRGPRX2可以触发不依赖IgE的激活（脱粒），这可能导致多种症状，具体取决于受影响的组织。

This receptor is unique in that it can respond to a wide variety of ligands, including neuropeptides, proteases, cytokines, antimicrobial peptides and others. In response to MRGPRX2 activation, mast cells release histamine, tryptase, chymase, chemokines and cytokines, which can cause itchy hives, angioedema, type 2 inflammation (through engagement of the adaptive immune system) and chronic pruritus and pain.

这种受体的独特之处在于它可以响应多种配体，包括神经肽，蛋白酶，细胞因子，抗菌肽等。响应MRGPRX2激活，肥大细胞释放组胺，类胰蛋白酶，糜蛋白酶，趋化因子和细胞因子，可引起荨麻疹，血管性水肿，2型炎症（通过适应性免疫系统的参与）和慢性瘙痒和疼痛。

Evommune's pre-clinical data demonstrates that by blocking activation of MRGPRX2 and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell mediated diseases. In addition, due to its unique function on peripheral sensory neurons, EVO756 could provide fast relief of itch associated with inflammatory diseases, such as atopic dermatitis, by blocking MRGPRX2.

Evommune的临床前数据表明，通过阻断MRGPRX2的激活和肥大细胞的脱粒，EVO756有可能成为各种肥大细胞介导疾病的一流口服治疗药物。此外，由于其对外周感觉神经元的独特功能，EVO756可以通过阻断MRGPRX2快速缓解与炎症性疾病（如特应性皮炎）相关的瘙痒。

EVO756 represents a new, targeted approach to the treatment of these disorders with the potential for once-daily oral administration without the serious side effects observed with other approaches.

EVO756代表了一种新的，有针对性的治疗这些疾病的方法，有可能每天口服一次，而没有其他方法观察到的严重副作用。

About Evommune, Inc.

关于Evommune，Inc

Evommune, Inc., a Palo Alto based biotech company, is creating game-changing science to treat immune-mediated inflammatory diseases by discovering, developing, and delivering therapies that address symptoms and halt progressive disease.

Evommune，Inc.，一家总部位于帕洛阿尔托的生物技术公司，正在创造改变游戏规则的科学，通过发现、开发和提供治疗症状和阻止进行性疾病的疗法来治疗免疫介导的炎症性疾病。